{"name":"Theralink Technologies","slug":"theralink","ticker":"THER","exchange":"OTC","domain":"theralink.com","description":"Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. In addition, the company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. The company was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies, Inc.is headquartered in Golden, ","hq":"Golden, CO","founded":0,"employees":"16","ceo":"Jeffrey Busch","sector":"Precision Diagnostics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$615,149","metrics":{"revenue":635450,"revenueGrowth":51.8,"grossMargin":61.4,"rdSpend":166720,"netIncome":-30907505,"cash":24270,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-09-14","type":"deal","headline":"Theralink Technologies Announces Collaboration with Leading Pharmaceutical Company","summary":"Theralink Technologies has entered into a collaboration with a leading pharmaceutical company to develop and commercialize new diagnostic tests.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"earnings","headline":"Theralink Technologies Reports Strong Q2 2023 Earnings","summary":"Theralink Technologies reported strong Q2 2023 earnings, driven by growth in its diagnostic test sales.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5wTmwwWGJlbHZhZG96UTdCZUhfUEN6V0Q4QW1QcUNzelZKYVViZUt6OWJxZF9jbFkyLVZWTDQ1TTZnVUN6S29jZThMOWVBXzMzNXJ3?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"THER Stock Price, News & Analysis - Stock Titan","headline":"THER Stock Price, News & Analysis","sentiment":"neutral"},{"date":"2024-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2024-02-20","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-01-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2023-11-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-08-21","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBuM1FfMURoYmVDS1loZUZ3YzMwcUk1bGJQc01NZXhTVzhob3p6ei1jQmNpVUFGSWFRTUpVNEt6UXUzMF94ZHJTMHFTSjdzZkxZYm81aWhJRWlyNFBPdUY4?oc=5","date":"2023-08-11","type":"pipeline","source":"nature.com","summary":"People - nature.com","headline":"People","sentiment":"neutral"},{"date":"2023-06-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-05-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-05-15","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-05-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC","headline":"Material Event (8-K)","sentiment":"neutral"},{"date":"2023-02-21","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOSnQxVzJKUjJOdGUtSVFqNUx2UTZsMFV2MWZrMFhqVUxLZ2JOTFhYUkdpcVUyTG5NMzRocHdDWmR2cGw2bGJqMkFQX0Mtc1BUajFWdU96ZEduV2p6QXRxRlVkTy0wZkdadVJ4UjRGdl8xMzd3V2VSOXpoNDg3dmFod3I0cFVQdXVSbEo4aFdDZWhFMlE3MENfTXZDUmYtRHdzVk1aTmZwbVc1SFYzYmdCelJ2NEN3T2lTaURjZHBseFItcUhfNHJTUXBpWGFVbzdraXF2dWM4SFZ2R2REZm9v?oc=5","date":"2022-12-09","type":"pipeline","source":"Reuters","summary":"Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say - Reuters","headline":"Patient selection for AstraZeneca, Daiichi breast cancer drug needs improvement, experts say","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9pNlBiOENqT1BqTUlzM2tUaFB6cUVDVElndnJBdTZCUVBpYnNqSmFjNGtHeEFfZjJZOWZXSlg5c1BGdjlxQ1dZOUpDWU5jcXRpMHc?oc=5","date":"2021-05-10","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Theralink Technologies, Inc. (THER) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Theralink Technologies, Inc. (THER) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Foundation Medicine","Invitae","Exact Sciences"],"therapeuticFocus":["Oncology","Precision Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":124650,"revenuePeriod":"2023-09-30","revenueHistory":[{"value":124650,"period":"2023-09-30"},{"value":74,"period":"2015-02-28"},{"value":254,"period":"2014-12-31"},{"value":24,"period":"2014-02-28"}],"grossProfit":480559,"grossProfitHistory":[{"period":"2023-09-30","value":480559},{"period":"2022-09-30","value":343019},{"period":"2021-09-30","value":388148}],"rdSpend":166720,"rdSpendHistory":[],"sgaSpend":9145448,"operatingIncome":-8740696,"operatingIncomeHistory":[{"period":"2023-09-30","value":-8740696},{"period":"2022-09-30","value":-11640006},{"period":"2021-09-30","value":-5565979}],"netIncome":-30907505,"netIncomeHistory":[{"period":"2023-09-30","value":-30907505},{"period":"2022-09-30","value":-12741962},{"period":"2021-09-30","value":-5471649}],"eps":-0.01,"epsHistory":[{"period":"2023-09-30","value":-0.01},{"period":"2022-09-30","value":-0.002207},{"period":"2021-09-30","value":-0.001236}],"cash":997484,"cashHistory":[{"period":"2023-09-30","value":997484},{"period":"2022-09-30","value":393460},{"period":"2021-09-30","value":314151}],"totalAssets":2849794,"totalLiabilities":40965355,"totalDebt":19761627,"equity":-38115561,"operatingCashflow":-5774855,"operatingCashflowHistory":[{"period":"2023-09-30","value":-5774855},{"period":"2022-09-30","value":-5389695},{"period":"2021-09-30","value":-4780930}],"capex":-163380,"capexHistory":[{"period":"2023-09-30","value":-163380},{"period":"2022-09-30","value":-131611},{"period":"2021-09-30","value":-135702}],"freeCashflow":-5938235,"dividendsPaid":0,"buybacks":null,"employees":16,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0,"previousClose":0,"fiftyTwoWeekHigh":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"1.0E-4 - 0.001","fiftyDayAverage":0,"twoHundredDayAverage":0,"beta":59.72,"enterpriseValue":23737624,"forwardPE":0,"priceToBook":-0.01,"priceToSales":0.97,"enterpriseToRevenue":37.36,"enterpriseToEbitda":-3.16,"pegRatio":0,"ebitda":-7507841,"ebitdaMargin":0,"freeCashflow":-8987239,"operatingCashflow":-4961299,"totalDebt":23755742,"debtToEquity":0,"currentRatio":0,"returnOnAssets":-191.5,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":82.6,"institutionHeldPercent":0,"sharesOutstanding":6151499919,"floatShares":1069684321,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0,"epsForward":0,"revenuePerShare":0,"bookValue":-0.01,"officers":[{"age":79,"name":"Dr. Michael I. Ruxin M.D.","title":"Chief Medical Officer & Director"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.theralink.com","phone":"888 585 4923"}}